Terms: = Ovarian cancer AND APOBEC3B, ARP4, 9582, ENSG00000179750, DJ742C19_2, _phorbolin 3_, PHRBNL, FLJ21201, Q9UH17, bK150C2_2, APOBEC1L, ARCD3 AND Clinical Outcome
454 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. Long Non-Coding RNAs: Bridging cancer-Associated Thrombosis and clinical outcome of ovarian cancer Patients.
Marques IS; Tavares V; Savva-Bordalo J; Rei M; Liz-Pimenta J; de Melo IG; Assis J; Pereira D; Medeiros R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203310
[TBL] [Abstract] [Full Text] [Related]
3. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H; Li Y; Joutsiniemi T; Muranen T; Isoviita VM; Huhtinen K; Micoli G; Lavikka K; Marchi G; Hietanen S; Virtanen A; Hautaniemi S; Oikkonen J; Hynninen J
Gynecol Oncol; 2024 Jan; 180():91-98. PubMed ID: 38061276
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
6. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract] [Full Text] [Related]
8. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract] [Full Text] [Related]
9. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
10. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract] [Full Text] [Related]
11. Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract] [Full Text] [Related]
12. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
Li Y; Zhang J; Cai Y; Liu H; Yang W; Xu Y; Huang M
Biochem Biophys Res Commun; 2023 May; 658():107-115. PubMed ID: 37030064
[TBL] [Abstract] [Full Text] [Related]
13. Borderline With Bad Behavior: An Unusual Low-grade Serous Carcinoma With Dedifferentiation From a Serous Borderline Tumor.
Strickland AL; Maniar KP; Tanner E; Shanes E; Jennings L; Wei JJ
Int J Gynecol Pathol; 2023 May; 42(3):241-246. PubMed ID: 36867463
[TBL] [Abstract] [Full Text] [Related]
14. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
15. Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade ovarian Serous Carcinoma.
Ruano APC; Gadelha Guimarães AP; Braun AC; Flores BCTCP; Tariki MS; Abdallah EA; Torres JA; Nunes DN; Tirapelli B; de Lima VCC; Fanelli MF; Colombo PE; da Costa AABA; Alix-Panabières C; Chinen LTD
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499015
[TBL] [Abstract] [Full Text] [Related]
16. Is microcystic, elongated, and fragmented pattern of myometrial invasion in endometrioid endometrial carcinoma associated with survival?
Altındağ SD; Yiğit S; Şen S
Turk J Med Sci; 2022 Oct; 52(5):1569-1579. PubMed ID: 36422476
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
18. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
19. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract] [Full Text] [Related]
20. Expression of epithelial-mesenchymal transition biomarkers: Discoidin domain receptor 2, Snail-1, and Ovol-2 as predictors of clinical outcome in patients with epithelial ovarian carcinoma.
Harb OA; Elfeky MA; El-Beshbishi W; Obaya AA; Abdallah WM; Ibrahim A; Awd AA; Embaby A
J Cancer Res Ther; 2022; 18(4):1073-1082. PubMed ID: 36149163
[TBL] [Abstract] [Full Text] [Related]
[Next]
